The Female Health Co (FHCO)

1.03
0.01 0.96
NASDAQ : Consumer Goods
Prev Close 1.04
Open 1.04
Day Low/High 0.96 / 1.05
52 Wk Low/High 1.16 / 2.75
Volume 75.97K
Avg Volume 70.50K
Exchange NASDAQ
Shares Outstanding 31.34M
Market Cap 30.71M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS With FLOMAX®

The Female Health Company / Veru Healthcare Initiates Bioequivalence Clinical Trial Comparing Tamsulosin DRS With FLOMAX®

Stage 1 of Clinical Trial Designed to Select Formulation; NDA Filing Under the 505(b)(2) Regulatory Pathway Late 2017 / Early 2018 And Approval Expected by Mid to Late 2018

Female Health Company / Veru Healthcare Announces Advancement Of Male Infertility Drug Candidate Following FDA Advisory Committee Meeting

Female Health Company / Veru Healthcare Announces Advancement Of Male Infertility Drug Candidate Following FDA Advisory Committee Meeting

-MSS-722 to Advance into Phase 2 Study; Trial Expected to Commence in 2017-

The Female Health Company / Veru Healthcare Appoints New President Of Global Public Health Sector Division

The Female Health Company / Veru Healthcare Appoints New President Of Global Public Health Sector Division

Company Promotes Denise van Dijk to President of Global Public Health Sector Division

The Female Health Company/Veru Healthcare Invited To Present At FDA Advisory Committee Meeting On December 6, 2016

The Female Health Company/Veru Healthcare Invited To Present At FDA Advisory Committee Meeting On December 6, 2016

Company to Discuss Clinical Trial Design and Primary Clinical Endpoints for Phase 2 Study of Its Drug Candidate for Male Infertility

The Female Health Company Adjourns Special Meeting Of Shareholders To October 31, 2016

The Female Health Company Adjourns Special Meeting Of Shareholders To October 31, 2016

Remaining Proposals Close to Receiving the Required Super Majority Vote

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD

Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?

The Female Health Company Modifies Proxy Proposal Related To Merger Transaction

The Female Health Company Modifies Proxy Proposal Related To Merger Transaction

ISS Changes Recommendation to Favorable

The Female Health Company Announces Adjournment Of Special Meeting Of Shareholders To September 22, 2016

The Female Health Company Announces Adjournment Of Special Meeting Of Shareholders To September 22, 2016

Three Proposals Have Received Required Majority Vote, Three Other Proposals Close to Receiving Required Super Majority Vote

The Female Health Company Urges Shareholders To Vote For Proposed Merger Transaction With Aspen Park Pharmaceuticals

The Female Health Company Urges Shareholders To Vote For Proposed Merger Transaction With Aspen Park Pharmaceuticals

Special Shareholders' Meeting to be Held Tuesday, September 20, 2016

The Female Health Company And Aspen Park Pharmaceuticals Announce FDA Clears Pathway For Expedited Development Of Proprietary Drug

The Female Health Company And Aspen Park Pharmaceuticals Announce FDA Clears Pathway For Expedited Development Of Proprietary Drug

New Proprietary Formulation of Drug for Benign Prostatic Hyperplasia (BPH) Addresses Billion Dollar Market; Expects to Commence Three Week Bioequivalence Study in Fourth Quarter of 2016; Plans to Submit New Drug Application (NDA) in 2017

The Female Health Company Announces Special Shareholders Meeting Will Be Held September 20, 2016

The Female Health Company Announces Special Shareholders Meeting Will Be Held September 20, 2016

Meeting to Approve Matters Relating to Proposed Merger With Aspen Park Pharmaceuticals